Cardiology

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

Participants described how they use risk assessment, payer requirements, and patient preference to sequence PAH therapies.

Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.

Mathew Maurer, MD, discusses the results of the phase 3 REVEAL study, which highlighted this novel scanning technology’s capacity for identifying amyloidosis early.

Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time.

James Januzzi, MD, discusses the recently released guideline update and how it should change clinicians’ priorities in addressing and preempting HFpEF.

James Januzzi, MD, discusses his post-hoc analysis of the ATTRibute-CM study, revealing a potential predictive ratio between these 2 measurements.

Martin Maron, MD, discusses the results of his responder analysis of the trial, presented at HFSA 2026, and the implications for aficamten’s path towards approval.

These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.

James Udelson, MD, discusses the Cycle-2-PEF trial, which ultimately supports the inverse dose-response hypothesis from companion trial Cycle-1-REF.

James Udelson, MD, discusses the results of the Cycle-1-REF study, presented at HFSA 2026, that could support an inverse dose-response relationship with this PDE9 inhibitor.

A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.

Tochi Okwueze, DNP, discusses a pair of presentations at HFSA 2026 that confirm the efficacy of subcutaneous furosemide treatment for patients with HF.

Mustafa Ahmed, MD, discusses early results from the Gator SCALES-WHF trial, investigating furosemide as an alternative to in-hospital IV diuresis.

A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

Ulrich Jorde, MD, discusses the Doraya device’s positive results in the DORAYA-HF feasibility study and Revamp Medical’s plans for a pivotal trial in early 2027.

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care.